Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controversies about amyotrophic lateral sclerosis

L P Rowland1

  • 1Neurological Institute, Columbia Presbyterian Medical Center New York, NY 10032, USA.

Neurologia (Barcelona, Spain)
|December 1, 1996
PubMed
Summary

Amyotrophic lateral sclerosis (ALS) treatments show marginal benefits, questioning a new therapeutic era. Furthermore, the distinction between ALS and multifocal motor neuropathy is blurred, suggesting potential for reversible treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALS Untangled No. 20: the Deanna protocol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2013
Same author

HIV-related neuromuscular diseases: nemaline myopathy, amyotrophic lateral sclerosis and bibrachial amyotrophic diplegia.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2011
Same author

Study of 962 patients indicates progressive muscular atrophy is a form of ALS.

Neurology·2009
Same author

Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.

Neurology·2009
Same author

Transcranial magnetic stimulation in ALS: utility of central motor conduction tests.

Neurology·2009
Same author

Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.

Neurology·2007

Area of Science:

  • Neurology
  • Neurodegenerative Diseases
  • Motor Neuron Diseases

Background:

  • Amyotrophic lateral sclerosis (ALS) research has historically focused on limited therapeutic advancements.
  • Prior to the 1990s, controlled studies failed to demonstrate consistent benefits from ALS treatments.
  • The role of peripheral nerve involvement in ALS pathogenesis has been a subject of debate.

Purpose of the Study:

  • To evaluate the current therapeutic landscape for amyotrophic lateral sclerosis (ALS).
  • To investigate the potential overlap and distinction between ALS and multifocal motor neuropathy with conduction block (MMNCB).
  • To assess the clinical relevance of recently proposed ALS therapies.

Main Methods:

  • Review of controlled studies on ALS treatments introduced since the 1990s, including riluzole, insulin-like growth hormone, brain-derived neurotrophic factor, and gabapentin.
  • Comparative analysis of clinical and pathological features between "typical" ALS and multifocal motor neuropathy with conduction block (MMNCB).
  • Evaluation of the reversibility of MMNCB with immunoglobulin therapy.

Main Results:

  • Announced benefits for four different ALS agents (riluzole, insulin-like growth hormone, brain-derived neurotrophic hormone, gabapentin) are marginal or questionable, despite statistical significance.
  • Multifocal motor neuropathy with conduction block (MMNCB) shares clinical signs (active reflexes in weak muscles) and pathological features (anterior horn cell loss) with ALS.
  • MMNCB is a reversible condition when treated with immunoglobulin therapy.

Conclusions:

  • Current ALS therapies offer limited clinical benefit, challenging the notion of a new therapeutic era.
  • The rigid separation between ALS and MMNCB is no longer tenable due to shared clinical and pathological characteristics.
  • The potential reversibility of MMNCB suggests a need to reconsider the role of peripheral nerve pathology in motor neuron diseases.

Related Experiment Videos